A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
To assess the safety, efficacy, and tolerability of using lenvatinib and pembrolizumab together in patients with Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
1. Male or female over 18 years old
2. Stage IV Non-Small Cell Lung Cancer
18 - 120
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug (s) until the disease progresses, treatment is no longer tolerable, or the participant and/or the study investigator decide to stop treatment.
After finishing treatment, the study investigator will continue to watch participants for side effects and follow participant's condition until study completion.
Knight Clinical Trials Information Line
Merck Sharp & Dohme Corp